Lexicon Pharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 81

Employees

  • Stock Symbol
  • LXRX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.53
  • (As of Friday Closing)

Lexicon Pharmaceuticals General Information

Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Contact Information

Formerly Known As
Lexicon Genetics
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2445 Technology Forest Boulevard
  • 11th Floor
  • The Woodlands, TX 77381
  • United States
+1 (281)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2445 Technology Forest Boulevard
  • 11th Floor
  • The Woodlands, TX 77381
  • United States
+1 (281)

Lexicon Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexicon Pharmaceuticals Stock Performance

As of 20-Nov-2026, Lexicon Pharmaceuticals’s stock price is $1.53. Its current market cap is $681M with 445M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.53 $1.67 $1.10 - $2.68 $681M 445M 2.57M -$0.15

Lexicon Pharmaceuticals Financials Summary

As of 30-Sep-2026, Lexicon Pharmaceuticals has a trailing 12-month revenue of $38.5M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 702,961 360,109 109,789 260,930
Revenue 38,537 49,803 31,081 1,204
EBITDA (60,735) (48,290) (196,583) (171,196)
Net Income (62,353) (50,341) (200,403) (177,119)
Total Assets 242,021 184,987 298,420 229,429
Total Debt 53,536 62,819 108,397 106,064
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexicon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commerciali
Drug Discovery
The Woodlands, TX
81 As of 2025

New York, NY
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lexicon Pharmaceuticals Competitors (102)

One of Lexicon Pharmaceuticals’s 102 competitors is Axsome Therapeutics, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axsome Therapeutics Formerly VC-backed New York, NY
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
Intercept Pharmaceuticals Formerly VC-backed Morristown, NJ
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 102 competitors. Get the full list »

Lexicon Pharmaceuticals Patents

Lexicon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026206818-A1 Methods of preparing 2',6-bis(difluoromethyl)-5-fluoro-2,4'-bipyridine Pending 27-Mar-2025
WO-2026173576-A1 Combination therapy of a glp-1 receptor agonist and a adsls inhibitor for metabolic disorders Pending 13-Feb-2025
WO-2026174130-A1 Methods of treating metabolic disease and compositions useful therein Pending 13-Feb-2025
WO-2026174160-A1 Methods of treating metabolic disease and compositions useful therein Pending 13-Feb-2025
AU-2025221627-A1 Compounds and methods of their use Pending 16-Feb-2024 C07D401/12
To view Lexicon Pharmaceuticals’s complete patent history, request access »

Lexicon Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lexicon Pharmaceuticals Investments & Acquisitions (4)

Lexicon Pharmaceuticals’s most recent deal was a Merger/Acquisition with Symphony Icon for . The deal was made on 02-Aug-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Symphony Icon 02-Aug-2010 Merger/Acquisition Pharmaceuticals
Symphony Icon 01-Jun-2007 Joint Venture Pharmaceuticals
Coelacanth Chemical 12-Jul-2001 Merger/Acquisition Pharmaceuticals
DataWave Solutions Corporate Other Healthcare Technology Systems
To view Lexicon Pharmaceuticals’s complete investments and acquisitions history, request access »

Lexicon Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.05 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lexicon Pharmaceuticals’s complete esg history, request access »

Lexicon Pharmaceuticals FAQs

  • When was Lexicon Pharmaceuticals founded?

    Lexicon Pharmaceuticals was founded in 1995.

  • Where is Lexicon Pharmaceuticals headquartered?

    Lexicon Pharmaceuticals is headquartered in The Woodlands, TX.

  • What is the size of Lexicon Pharmaceuticals?

    Lexicon Pharmaceuticals has 81 total employees.

  • What industry is Lexicon Pharmaceuticals in?

    Lexicon Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Lexicon Pharmaceuticals a private or public company?

    Lexicon Pharmaceuticals is a Public company.

  • What is Lexicon Pharmaceuticals’s stock symbol?

    The ticker symbol for Lexicon Pharmaceuticals is LXRX.

  • What is the current stock price of Lexicon Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Lexicon Pharmaceuticals is $1.53.

  • What is the current market cap of Lexicon Pharmaceuticals?

    The current market capitalization of Lexicon Pharmaceuticals is $681M.

  • What is Lexicon Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Lexicon Pharmaceuticals is $38.5M.

  • Who are Lexicon Pharmaceuticals’s competitors?

    Axsome Therapeutics, ACADIA Pharmaceuticals, Intercept Pharmaceuticals, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 102 competitors of Lexicon Pharmaceuticals.

  • What is Lexicon Pharmaceuticals’s annual earnings per share (EPS)?

    Lexicon Pharmaceuticals’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process